X

Trial Profile

SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 03 Jun 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Clofutriben (Primary)
Indications Adrenal gland disorders; Cushing syndrome
Focus Therapeutic Use
Acronyms ACSPIRE
Sponsors Sparrow Pharmaceuticals

Most Recent Events

30 May 2024 According to a Sparrow Pharmaceuticals media release, interim data from ongoing clinical trials in patients with ACTH-dependent Cushing's syndrome will be presented by the David Katz during SY55 - Development of Novel Endocrine Therapies by Inhibiting Steroid Biosynthesis session.
16 May 2024 Planned number of patients changed from 150 to 30.
16 May 2024 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com